g(m2)-ganglioside and HIV-Infections

g(m2)-ganglioside has been researched along with HIV-Infections* in 3 studies

Reviews

1 review(s) available for g(m2)-ganglioside and HIV-Infections

Article	Year
Human IgM antibody therapy for HIV-1 infection. Microbiology and immunology, 1999, Volume: 43, Issue:8 Topics: Animals; Antibodies, Monoclonal; Complement System Proteins; G(M2) Ganglioside; Gangliosides; HIV Infections; HIV-1; Humans; Immunoglobulin M; Immunotherapy; RNA, Viral; Survivors; Viral Load	1999

Other Studies

2 other study(ies) available for g(m2)-ganglioside and HIV-Infections

Article	Year
The IgM antibody level against ganglioside GM2 correlates to the disease status of HIV-1-infected patients. Microbiology and immunology, 2000, Volume: 44, Issue:5 HIV-1 infection induces the expression of high level of GM2 ganglioside on infected cells and IgM antibody (Ab) against GM2 can cause complement (C)-mediated cytolysis of HIV-1-infected cells. Since GM2 is immunogenic in human, we proposed that an anti-GM2 IgM Ab may be produced by some HIV-1-infected patients and the titer of this Ab might provide some insight into the progress of the disease. On this premise, the amount of IgM Ab against GM2 was determined in 124 HIV-1-infected patients and 111 seronegative donors. As expected, the anti-GM2 IgM Ab titers of the patients was significantly higher than that of the seronegative donors while the total IgM levels remained unchanged. In addition, we determined the CD4+ cell count and the HIV-RNA load in the HIV-1-infected patients. The results showed a positive correlation between the anti-GM2 IgM Ab titer and CD4+ cell count but a negative correlation between the anti-GM2 IgM Ab titer and HIV-RNA load. These suggest that anti-GM2 IgM Ab induced and/or enhanced by HIV-1 infection causes C-mediated cytolysis of HIV-1-infected cells in vivo to a certain extent, and may help lower the plateau level of the HIV-RNA load. Therefore, the amount of IgM Ab against GM2 may be related to the prognosis of HIV-1 infected patients. Topics: CD4 Lymphocyte Count; Cell Survival; G(M2) Ganglioside; HIV Infections; HIV-1; Humans; Immunoglobulin M; In Vitro Techniques; Leukocytes, Mononuclear; RNA, Viral; Viral Load	2000
Human IgM monoclonal antibody to ganglioside GM2 and complement suppress virus propagation in ex vivo cultures of lymphocytes from HIV-1 infected patients. Microbiology and immunology, 1999, Volume: 43, Issue:7 HIV-1 infection induces aberrant ganglioside GM2 expression on infected cell lines, and human IgM anti-GM2 monoclonal antibody (L55 Ab) together with normal fresh human serum (FHS) as a source of complement causes complement mediated cytolysis of HIV-1 infected cells as well as HIV-1 particles. We report here that high expression of GM2 was also detected on HIV-1 infected lymphocytes from HIV-1 seropositive patients. L55 Ab effectively suppressed the generation of HIV in the presence of FHS in primarily cultured lymphocytes from HIV-1 infected patients in ex vivo experiments, and the suppression was enhanced additively by AZT. These data suggest that L55 Ab may increase the therapeutic effect of chemotherapy. Topics: Antibodies, Monoclonal; Cells, Cultured; Complement System Proteins; G(M2) Ganglioside; HIV Infections; HIV-1; Humans; Immunoglobulin M; Lymphocytes; Virus Replication	1999

Article

Year

The IgM antibody level against ganglioside GM2 correlates to the disease status of HIV-1-infected patients.

Microbiology and immunology, 2000, Volume: 44, Issue:5

HIV-1 infection induces the expression of high level of GM2 ganglioside on infected cells and IgM antibody (Ab) against GM2 can cause complement (C)-mediated cytolysis of HIV-1-infected cells. Since GM2 is immunogenic in human, we proposed that an anti-GM2 IgM Ab may be produced by some HIV-1-infected patients and the titer of this Ab might provide some insight into the progress of the disease. On this premise, the amount of IgM Ab against GM2 was determined in 124 HIV-1-infected patients and 111 seronegative donors. As expected, the anti-GM2 IgM Ab titers of the patients was significantly higher than that of the seronegative donors while the total IgM levels remained unchanged. In addition, we determined the CD4+ cell count and the HIV-RNA load in the HIV-1-infected patients. The results showed a positive correlation between the anti-GM2 IgM Ab titer and CD4+ cell count but a negative correlation between the anti-GM2 IgM Ab titer and HIV-RNA load. These suggest that anti-GM2 IgM Ab induced and/or enhanced by HIV-1 infection causes C-mediated cytolysis of HIV-1-infected cells in vivo to a certain extent, and may help lower the plateau level of the HIV-RNA load. Therefore, the amount of IgM Ab against GM2 may be related to the prognosis of HIV-1 infected patients.

Topics: CD4 Lymphocyte Count; Cell Survival; G(M2) Ganglioside; HIV Infections; HIV-1; Humans; Immunoglobulin M; In Vitro Techniques; Leukocytes, Mononuclear; RNA, Viral; Viral Load

2000

Human IgM monoclonal antibody to ganglioside GM2 and complement suppress virus propagation in ex vivo cultures of lymphocytes from HIV-1 infected patients.

Microbiology and immunology, 1999, Volume: 43, Issue:7

HIV-1 infection induces aberrant ganglioside GM2 expression on infected cell lines, and human IgM anti-GM2 monoclonal antibody (L55 Ab) together with normal fresh human serum (FHS) as a source of complement causes complement mediated cytolysis of HIV-1 infected cells as well as HIV-1 particles. We report here that high expression of GM2 was also detected on HIV-1 infected lymphocytes from HIV-1 seropositive patients. L55 Ab effectively suppressed the generation of HIV in the presence of FHS in primarily cultured lymphocytes from HIV-1 infected patients in ex vivo experiments, and the suppression was enhanced additively by AZT. These data suggest that L55 Ab may increase the therapeutic effect of chemotherapy.

Topics: Antibodies, Monoclonal; Cells, Cultured; Complement System Proteins; G(M2) Ganglioside; HIV Infections; HIV-1; Humans; Immunoglobulin M; Lymphocytes; Virus Replication

1999